Alzheimer's disease: will advances made in the past turn the tide?
Pharmacy Benefits Management & Strategic Health Group, Department of Veterans Affairs, Chicago, IL, USA. t-semla@northwestern.edu
Todd P
TP
Semla
D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000266:history*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D000077265:Donepezil; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007189:Indans / Q000627:therapeutic use; D008559:Memantine / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D013619:Tacrine / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D014150:Antipsychotic Agents; D002800:Cholinesterase Inhibitors; D018691:Excitatory Amino Acid Antagonists; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007189:Indans; D010880:Piperidines; D013619:Tacrine; D000077265:Donepezil; D008559:Memantine